Introduction {#S1}
============

The increased use of hematopoietic stem cell transplantation (HCT) among children, coupled with an increase in survival, has led to a rise in the number of young HCT survivors.\[[@R1],[@R2]\] Osteonecrosis, a debilitating skeletal morbidity\[[@R3],[@R4]\] is one complication that can compromise quality of life among these survivors. Osteonecrosis is a challenge to treat in this population because it is often identified in advanced stages, and in multiple joints, when the only available treatment is joint replacement. Surgery can be accompanied by high rates of infection because of immunosuppression, and often requires revision because of hardware failure in these young patients.\[[@R5],[@R6]\]

Although published reports describe osteonecrosis in adults or mixed populations,\[[@R2],[@R3],[@R7]--[@R11]\] studies describing osteonecrosis exclusively in pediatric population are few.\[[@R12]--[@R16]\] A wide range of incidence rates, 3.9--44.0%, following pediatric HCT is reported. Among adults, the incidence of osteonecrosis is higher in allogeneic than in autologous HCT survivors\[[@R3],[@R7],[@R11]\] Previously reported risk factors for osteonecrosis include acute and chronic graft-versus-host disease (GVHD) requiring steroids, older age at transplantation, and a primary diagnosis of leukemia or aplastic anemia\[[@R2],[@R3],[@R9],[@R11],[@R12]\]. Limiting understanding of osteonecrosis in pediatric HCT patients are the diverse diagnostic criteria used in previous studies\[[@R3],[@R8],[@R11],[@R12],[@R17],[@R18]\], ranging from symptom-based diagnosis and plain radiographs to magnetic resonance studies (MR).

We reviewed prospectively acquired serial MRs in children who underwent a single alloHCT at our institution from December 2000 to September 2007. We sought to assess the prevalence, associated risk factors, and longitudinal changes observed over time in the development of osteonecrosis after alloHCT. This knowledge provides an assessment of the magnitude of this problem and an understanding of the timing of onset of osteonecrosis in this vulnerable young population.

Methods {#S2}
=======

Study population {#S3}
----------------

We retrospectively reviewed medical records and MRs of children who underwent a single alloHCT at St. Jude Children's Research Hospital between December 2000 and September 2007. Only patients for whom post-HCT MRs of hips, knees, or both were available were included in the cohort. To assess the representativeness of the study sample, clinical characteristics of the cohort were compared with those of the excluded population.

Since January 2002, patients undergoing alloHCT at St. Jude have undergone baseline MR of the hips and knees at the time of alloHCT and follow-up protocol-driven imaging of hips and knees annually afterward. If bone marrow transplantation must be performed urgently, then pre-alloHCT MR imaging may be omitted. If the second follow-up MR is normal and the patient is asymptomatic, then no further imaging is done. If the study is abnormal or symptoms persist during the second annual imaging study, then the patient is followed until imaging findings peak or symptoms resolve.

Institutional review board (IRB) approval was obtained for this study, and data were managed in accordance with the Health Insurance Portability and Accountability Act of 1996. All patients underwent IRB-approved treatment for their primary disease under institutional or cooperative group protocols.

Osteonecrosis {#S4}
-------------

Patients being evaluated for osteonecrosis had coronal noncontrast T~1~-weighted and short tau inversion recovery (STIR) imaging of the hips and/or knees and sagittal fast low angle shot MR 2-D imaging of the articular surfaces. MRs were performed with either a Siemens 1.5-T Symphony or a Vision MR unit (Siemens, Inc., Erlangen, Germany). MRs were reviewed and interpreted by an experienced pediatric radiologist (SCK) blinded to presence or absence of clinical symptoms. As described previously \[[@R5],[@R19],[@R20]\], osteonecrosis was defined as a geographic area of decreased signal on T1-weighted and increased signal on STIR images.

Osteonecrosis locations were classified as epiphyseal, metaphyseal, or diaphyseal.\[[@R19]\] Because the extent of epiphyseal involvement is an important predictor of joint outcome,\[[@R5]\] we categorized the extent of epiphyseal involvement as ≥30% or \<30% of the weight-bearing surface. Thus, hip joint involvement was coded according to the involvement of the capital femoral epiphysis, and knees were coded as involved if an osteonecrosis lesion was present in either the distal femoral or the proximal tibial epiphysis. For patients who underwent multiple MRs after alloHCT (N=91), the MR revealing the most severe osteonecrosis was used for calculating prevalence and analyzing risk factors. We also evaluated the distribution and pattern of multiple joint involvement.

Longitudinal changes in osteonecrotic lesions {#S5}
---------------------------------------------

Serial MRs were evaluated to assess the evolution of osteonecrosis over time. Longitudinal changes were documented separately for knees and hips by comparing annual MRs after alloHCT and by comparing pre- and post-alloHCT MRs for patients for whom pre-alloHCT MRs were available.

Any case that resolved completely over time (hip or knee) bilaterally was classified as "resolved;" any decrease in size of the osteonecrosis lesion was categorized as "regression." Patients with negative pre-alloHCT MR who had osteonecrosis lesions after alloHCT and those identified with osteonecrosis after alloHCT for the first time were considered "new cases." Cases with an increase in the size of existing osteonecrosis lesions were labeled as "progression." We also collected information about surgical interventions for osteonecrosis during the follow-up period.

Transplantation {#S6}
---------------

All patients underwent alloHCT on IRB-approved protocols. Grafts were obtained from human leukocyte antigen (HLA)-identical siblings, matched unrelated donors (matched for five or six HLA loci), or mismatched family members. Patients with hematologic malignancies were conditioned with myeloablative total body irradiation (TBI)-based conditioning (12 Gy in 8 fractions over 4 days in doses of 150 cGy per fraction) or with reduced-intensity fludarabine-based conditioning (40 mg/m^2^ for 5 days). Patients with non-malignant conditions were given busulfan-based conditioning (8--16 mg/kg). All recipients received either a calcineurin inhibitor or mycophenolate mofetil for GVHD prophylaxis.

GVHD was graded according to standard criteria.\[[@R21],[@R22]\] Patients with grade 2 to 4 acute GVHD were treated with methylprednisolone (1--2 mg/kg daily). If GVHD remained at grade 2 or more for more than 7 days or progressed, secondary agents were started, such as a calcineurin inhibitor or mycophenolate mofetil that the patient was not receiving.

Risk factors {#S7}
------------

We considered associations between osteonecrosis after alloHCT and the following risk factors: sex, race, age at time of alloHCT (i.e., \<10 years or ≥10 years), age at primary diagnosis, primary diagnosis (lymphoid malignancies and aplastic anemia vs. others), body mass index (BMI) at time of alloHCT (normal and underweight vs. overweight and obese), donor type (related vs. unrelated), conditioning regimen (TBI vs. non-TBI), acute GVHD (none vs. grade 1 or higher), chronic GVHD (none vs. limited, none vs. extensive), and physis status at the time of HCT (open vs. closed). BMI at the time of HCT was calculated only for patients older than 2 years, per Centers for Disease Control and Prevention (CDC) criteria ([www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html](www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html)).\[[@R23]\] Since physeal development was bilaterally similar (correlation coefficient\>0.95 with p\<0.0001; results not shown) and there were only minor differences between hips and knees (correlation coefficient around 0.85 with p\<0.0001), we used a majority rule to combine all six physis statuses into one status value. For patients with more than half physis statuses as "closed," we defined the physis status as "closed."

As previously described, \[[@R19]\] malignant conditions were categorized as lymphoid (i.e., acute lymphoblastic leukemia, non-Hodgkin lymphoma \[NHL\], and Hodgkin disease) or non-lymphoid (malignant conditions other than described as lymphoid). Because statistical power for eliciting the effect of individual treatment regimens was limited and individual cumulative doses of steroids received by each patient were unavailable, primary diagnoses were categorized on the basis of contemporary treatment protocols to assess the potential effect of steroid exposure. Diagnoses were grouped as follows: lymphoid malignancies and aplastic anemia vs. other conditions (i.e. non-lymphoid malignancies and sickle-cell disease, immunodeficiency syndromes, osteopetrosis, I-cell disease, Hurler disease, thromboasthenia, and Glanzmann disease).

Statistical analyses {#S8}
--------------------

Descriptive statistics were used to describe the study population by sex, race, primary diagnosis, age at the time of MR; age, BMI and physis status at the time of HCT, conditioning regimen, product type, donor type, donor match type, acute and chronic GVHD grades and duration of chronic GVHD.

Osteonecrosis prevalence rates were calculated for epiphyseal involvement of any of the four lower extremity joints and for hips and knees separately. Time to development of osteonecrosis after alloHCT was calculated only for children with negative or undetected osteonecrosis before alloHCT. The pattern and distribution of joint involvement was examined by evaluating the number of lower extremity joints involved at the time when the earliest MR showed the highest grade of osteonecrosis. Cumulative incidences of osteonecrosis after alloHCT were estimated with death as the competing event.

We used a generalized estimating equation (GEE) models\[[@R24]\] to estimate the incidence of osteonecrosis over time. Independent variables with a significance level of 0.01 in univariate analysis were included in the multivariate GEE model. Because sickle cell anemia\[[@R25]\] is highly correlated with black race, the analysis was repeated with and without sickle cell patients in the model.

Data were analyzed by using SAS (Version 9.13; SAS Institute, Inc., Cary, NC). Statistical significance was set at a p-value of 0.05.

Results {#S9}
=======

Demographic characteristics of the study population {#S10}
---------------------------------------------------

Of the 344 consecutive patients who underwent allogeneic HCT at St. Jude Children's Research Hospital from December 2000 to September 2007, 149 (84 males) children (median age at time of alloHCT 11 years (range, 0.5--21 years)) underwent at least one post-alloHCT MR of hips and/or knees irrespective of symptoms, and had undergone a single alloHCT ([Figure 1](#F1){ref-type="fig"}). Demographic characteristics of the cohort are shown in [Table 1](#T1){ref-type="table"}. 116 patients had alloHCT for malignant diseases and 33 for non-malignant conditions. Median time to follow-up from the date of alloHCT was 32.6 months (range, 2.8--97.2 months). When compared to excluded patients, the study population was older at the time of alloHCT, had fewer males and more often received total body irradiation (TBI). Patients older than 10 years of age were more likely to have undergone pre-alloHCT MR than those younger than 10 years (p\<0.0001) at time of bone marrow transplantation.

Prevalence, severity and time to development of osteonecrosis {#S11}
-------------------------------------------------------------

When considering all four joints, the prevalence of osteonecrosis was 29.5% (44/149); 45.5% (20/44) had ≥30% epiphyseal involvement. The prevalence of osteonecrosis in the knees was 28.2% (40/142), greater than the prevalence of 9% (13/143) in hips. Fourteen of the 40 patients with osteonecrosis of the knees, 14 had ≥30% epiphyseal involvement. Twelve of the 13 patients with hip osteonecrosis had ≥30% epiphyseal involvement Cumulative incidence plots ([Figure 2](#F2){ref-type="fig"}) show that 52.3% (23/44) of osteonecrosis cases were identified in the first and 97.8% (43/44) by the third annual scans.

Among the 44 children with osteonecrosis after alloHCT, 14 had evidence of osteonecrosis on pre-alloHCT MR. The median times to development of osteonecrosis in any joint in children with unknown pre-alloHCT osteonecrosis status (n=16), and in children with negative pre-alloHCT status (n=14), were 12.4 months (0.2--38.7 months) and 12.2 months (0.2--24.4 months), respectively.

Pattern of joint involvement {#S12}
----------------------------

Of the 44 patients with osteonecrosis, 30 (68.2%) had multiarticular involvement; most commonly, bilateral knee involvement (21/44). Three of these patients had bilateral hip coupled with uni- or bilateral knee involvement. Of the 14 of 76 children who had both pre- and post-alloHCT MR, nine were found to have multiarticular involvment.

Longitudinal changes {#S13}
--------------------

Among the 149 patients, 58 had only one post-HCT imaging study available for review, 32 had two, and 59 had more than two. Pre-HCT imaging studies were available for 76 children ([Figure 1](#F1){ref-type="fig"}).\[[@R19]\]

During the first year after alloHCT, hip MRs were available for 124 and knee MRs for 129 patients ([Table 3](#T3){ref-type="table"}). Of the 129 patients with first annual hip MRs, 58 also had pre-alloHCT MRs; two showed complete resolution, and seven new cases of osteonecrosis were identified. For knees, 57 of 129 had pre-alloHCT MRs; two showed complete resolution, one regressed, and 25 new cases were identified.

During the second year after alloHCT, 124 patients had hip MRs for both the first and second year, and 129 had knee MRs for both years. On comparing serial MRs, regression was observed in one hip and one knee and complete resolution in four knees ([Table 4](#T4){ref-type="table"}). The four patients with complete resolution of lesions ranged in age from 2 years 8 months to 14 years 8 months at primary diagnosis and 3 years 2 months to 6 years 6 months at time of alloHCT. Three of the four were skeletally immature as evidenced by physeal patency at time of alloHCT and were shown to have epiphyseal involvement of \< 30%. The patient with closed physes had epiphyseal involvement of at least 30%. Three of the four patients had a primary diagnosis of acute lymphoblastic leukemia; one had acute myelogeneous leukemia. All four patients were of healthy body weight; all had received total body irradiation. Two received 6/6 HLA matched sibling and two HLA 6/6 matched unrelated donor cells. Three patients developed acute grade 1 GVHD; one developed no acute GVHD. All four developed chronic GVHD (two limited, two extensive and all four with duration of less than 6 months).

New cases of osteonecrosis were identified in one hip and five knees as ([Table 4](#T4){ref-type="table"}). Among the 13 involved hips identified during follow-up, four have undergone total hip arthroplasty (THA). Two of these had THA before alloHCT and two afterward. In one patient, transient improvement in symptoms was documented after alloHCT, but subsequent progression required THA. All of these patients underwent core decompressions of the involved joints before THA.

Risk factors {#S14}
------------

Among the various risk factors studied, only pre-alloHCT osteonecrosis status (OR 13.50; 95% CI 2.64--68.92) and age ≥ 10 years at the time of alloHCT (OR 4.00; 95% CI 1.00--16.67) were associated with greater odds of osteonecrosis in the 3 years following alloHCT ([Table 5](#T5){ref-type="table"}). Black race was found to be significant on univariate analysis p=0.0431, but was not significant in models when patients with sickle cell disease were excluded. Other risk factors studied were not associated with an increased risk of osteonecrosis.

Discussion {#S15}
==========

Our analysis of prospectively acquired longitudinal MRs of hips and knees revealed a prevalence of osteonecrosis in almost 30% of the children in the first 3 years after a single alloHCT. Although knees were more often involved, hip involvement was more extensive. We observed complete resolution of osteonecrosis after alloHCT in two patients' hips and six patients' knees. Of those, one had osteonecrosis lesion involving more than 30% of the epiphyseal surface before alloHCT.

The prevalence of 30% is higher than previously reported rates that have been based on symptoms or less sensitive diagnostic techniques, but approach rates reported in MR-based studies;\[[@R12]--[@R16],[@R26]--[@R30]\] symptom-based studies may underreport early-stage osteonecrosis. As we focused only on epiphyseal lesions of hips and knees\[[@R3]\], our findings may underestimate osteonecrosis-associated skeletal morbidity.

Aplastic anemia and ALL are well recognized risk factors for osteonecrosis following HCT\[[@R2],[@R9]\]; we found no association in our post-alloHCT cohort. Our results conflict with those of our previous study, \[[@R19]\] where we evaluated risk factors for osteonecrosis before alloHCT and found some indication that a primary diagnosis of aplastic anemia or lymphoid malignancies may be a risk factor. As none of the published studies considered pre-alloHCT status, this discrepancy may be attributable to our risk factor analysis model adjusted for pre-alloHCT status.

The median time to development of osteonecrosis in our MR-based study was 12.3 months, a much shorter time period than reported in previous studies\[[@R3],[@R7],[@R8],[@R10],[@R12],[@R31]\]. We found that only age older than 10 years and pre-existing osteonecrosis were predictive of an osteonecrosis in the 3 years following alloHCT. When future interventions that target early detection and prevention of osteonecrosis in the first 3 years following transplant are available, older children and children with existing lesions will be prime candidates for screening.

Older age has been consistently recognized as a risk factor for osteonecrosis \[[@R4],[@R8]\]. White race has also been implicated as a risk factor for osteonecrosis \[[@R32]\]. We found no such association in our study population. Race was found to be statistically significant on univariate analysis but as sickle cell disease is strongly associated with black race, \[[@R25]\] we repeated analysis after excluding sickle cell patients and found no such association. Our cohort included 16 sickle cell patients, of whom eight were found to have osteonecrosis. Osteonecrosis is a well-known morbidity of sickle cell disease that has been positively associated with the frequency of vaso-occlusive pain crises and elevated hematocrit \[[@R33]\]. This morbidity has been reported in 10--16% of symptomatic patients assessed radiographically \[[@R30],[@R34],[@R35]\] and in up to 40% of patients radiographically examined regardless of symptoms \[[@R29]\]. The high 50% prevalence of osteonecrosis we found in our sickle cell patients is similar to the MR-detected incidence of 65% reported after a follow-up period of 4 to 5 years \[[@R36]\].

Unlike other investigators, \[[@R10],[@R13]\], we found no significant increase in risk for osteonecrosis among those who received TBI, possibly because our patients received very small doses of radiation per fraction (150 cGy/fraction twice daily).

The findings that pre-alloHCT osteonecrosis status was a risk factor for post-alloHCT osteonecrosis, and that GVHD was not an important risk factor during 3 years of follow-up supports the multiple hit theory of osteonecrosis; \[[@R37],[@R38]\] steroid exposure imparts secondary rather than primary insult on the osteonecrosis pathway. Previous investigations, primarily conducted in adult populations, have identified an association between higher grade or longer duration of GVHD (acute or chronic) and osteonecrosis \[[@R2],[@R3],[@R7],[@R8],[@R11],[@R39],[@R40]\], attributing risk to prolonged exposure to steroids. We found no such association. Prolonged exposure to steroids was not a prominent characteristic of our population. In our study, only 12% of children developed GVHD that required steroid therapy treatment for longer than 6 months. As our population was followed for only 3 years post-alloHCT, it is possible that children in our cohort with chronic GVHD who eventually experience prolonged steroid exposure will develop osteonecrosis. Our analysis underscores the importance of pre-alloHCT therapeutic exposures, and the likelihood of osteonecrosis following alloHCT, and encourages us to explore novel options to curtail the compounding osteotoxic effect of glucocorticoids\[[@R41]\].

Another compelling finding in our study was regression or resolution of post-alloHCT osteonecrosis in several children. Of the patients whose osteonecrosis resolved completely, one initially had more than 30% epiphyseal involvement. As a standard of care at our institution, all children with osteonecrosis are managed conservatively until pain or restricted movement develops. At that time, analgesics and/or surgical options are offered. Whether these osteonecrosis regressions were the natural course of disease, a response to joint protection measures instituted in physical therapy\[[@R42]\], or a result of a protective effect of alloHCT is unknown.

Our data preclude us from making definitive conclusions about osteonecrosis recovery due to alloHCT. However, limited evidence\[[@R43]--[@R46]\] suggests that stem cells have a role in regenerative medicine. This reparative phenomenon may in part be attributed to mesenchymal stem cells or primitive hematopoietic cells with osteoblastic potential\[[@R43]\] engrafted during alloHCT. Increased chemotaxis by cytokines released from the necrosed bone may also facilitate mesenchymal stem cell homing and vascular proliferation\[[@R47],[@R48]\].

Our findings should be interpreted with caution since the diverse primary diagnoses limited our ability to estimate the effect of disease pathophysiology or its treatment on the evolution of osteonecrosis. Because our study population was slightly older than patients who did not receive imaging, and because older age has been consistently associated with development of osteonecrosis, our estimated incidence for osteonecrosis in the first 3 years following alloHCT may be inflated. Finally, although the lesions we detected in this cohort developed during the first 3 years after alloHCT, our study results do not provide information needed to ascertain delayed onset osteonecrosis in this population. Despite these limitations, we provide information about the prevalence and risk factors for development of osteonecrosis during the first 3 years after alloHCT among children.

Our results lead us to conclude that future screening and preventive strategies for osteonecrosis in children undergoing alloHCT should focus on pre-alloHCT risk factors among children who are older than 10 years of age. We recommend prospective controlled trials to determine the roles of physical therapy, mesenchymal stem cell therapy, and other novel interventions for treating early osteonecrotic lesions.

Supplementary Material {#S16}
======================
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![Cumulative incidence of osteonecrosis\
**Note:** The intercept (in red) has been shown to be 12% (SE 2.68%), to emphasize that 14 patients were already known to have osteonecrosis at the time of alloHCT because of magnetic resonance imaging done prior to alloHCT.\
**Abbreviations:** CI, cumulative incidence; ON, osteonecrosis](nihms328223f2){#F2}

###### 

Demographic data for patients who received magnetic resonance imaging after allogeneic HCT

  Demographic variable                                 Frequency (n=149)   Percentage (%)
  ---------------------------------------------------- ------------------- ----------------
  **Sex**                                                                  
   Male                                                84                  56
   Female                                              65                  44
  **Race**                                                                 
   Other                                               29                  20
   Black                                               28                  19
   White                                               92                  62
  **Diagnosis**                                                            
   Nonmalignant                                        33                  22
   Malignant                                           116                 78
  **Primary diagnosis**                                                    
   Others                                              87                  58
   Lymphoid malignancies & aplastic anemia             62                  43
  **Survival status**                                                      
   Dead                                                28                  19
   Alive                                               121                 81
  **BMI at alloHCT**[\*](#TFN1){ref-type="table-fn"}                       
   Normal & underweight                                96                  67
   Overweight & obese                                  47                  33
  **Age at MR**[\*\*](#TFN2){ref-type="table-fn"}                          
   \<10                                                51                  34
   ≥10                                                 98                  66
  **Age at alloHCT**                                                       
   \<10                                                65                  44
   ≥10                                                 84                  56
  **Conditioning regimen**                                                 
   Total body irradiation                              101                 68
   No-total body irradiation                           48                  32
  **Physis status at allo HCT**                                            
   Closed                                              42                  28
   Open                                                107                 72
  **Acute GVHD maximum Overall grade**                                     
   No acute GVHD                                       30                  20
   Grade 1, 2                                          81                  54
   Grade 3, 4                                          38                  26
  **Chronic GVHD grade**                                                   
   No chronic GVHD                                     92                  62
   Limited                                             26                  18
   Extensive                                           31                  21
  **Donor type**                                                           
   Unrelated                                           57                  381
   Related                                             92                  62
  **Donor match type**                                                     
   HLA-matched siblings                                49                  33
   Matched unrelated donors                            57                  38
   Mismatched family members                           43                  29
  **Product type**                                                         
   HPC-A                                               47                  32
   HPC-C                                               1                   1
   HPC-M                                               101                 68
  **Duration of chronic GVHD**                                             
   No prior chronic GVHD                               92                  62
   Duration ≤ 6 months                                 39                  26\.
   Duration \> 6 months                                18                  12

BMI calculated only for children more than 2 years old.

Age at the first peak osteonecrosis, if a patient did not have any positive imaging result; age at the last imaging date was used.

Abbreviations: alloHCT, allogeneic hematopoietic stem cell transplantation; BMI, Body mass index; GVHD, Graft vs. host disease;; HPC-A, Hematopoietic stem cell from peripheral blood; HPC-M, Hematopoietic stem cell from Marrow; HPC-C, Hematopoietic stem cell from cord; MR, magnetic resonance imaging

###### 

Characteristics of study cohort (*N* =149) versus those who were excluded (*N* = 195)

  Characteristics        Total *n* (%)                             Excluded *n (*%)   Study Cohort *n* (%)   P value    
  ---------------------- ----------------------------------------- ------------------ ---------------------- ---------- -------------------------------------------
  Gender                 Male                                      216 (63)           132 (68)               84 (56)    **0.0332**[•](#TFN4){ref-type="table-fn"}
                         Female                                    128 (37)           63 (32)                65 (44)    
  Race                   White                                     213 (62)           121 (62)               92 (62)    0.8501
                         Black                                     68 (20)            40 (21)                28 (19)    
                         Other                                     63 (18)            34 (17)                29 (20)    
  Diagnosis              Non-malignant                             68 (20)            35 (18)                33 (22)    0.3422
                         Malignant                                 276 (80)           160 (82)               116 (79)   
  Primary Disease        Others                                    212 (62)           125 (64)               87 (58)    0.3143
                         Lymphoid Malignancies + Aplastic Anemia   132 (38)           70 (36)                62 (42)    
  Age at alloHCT         Age at alloHCT \<10                       174 (52)           109 (56)               65 (44)    **0.0294**[•](#TFN4){ref-type="table-fn"}
                         Age at alloHCT \>=10                      170 (49)           86 (44)                84 (56)    
  Donor Type             Unrelated                                 113 (33)           56 (29)                57 (38)    0.0650
                         Related                                   231 (67)           139 (71)               92 (62)    
  Conditioning regimen   Total Body Radiation                      204 (59)           103 (54)               101 (68)   **0.0103**[•](#TFN4){ref-type="table-fn"}
                         No TBI                                    137 (40)           89 (46)                48 (32)    

Values depicted in bold were statistically significant

Abbreviations: alloHCT, allogeneic hematopoietic stem cell transplantation; TBI, Total body irradiation

###### 

Longitudinal changes in the osteonecrotic lesions in children observed with magnetic resonance imaging during the first year after alloHCT.

  MR results before alloHCT   MR results one year after alloHCT    Total                                                                                                    
  --------------------------- ------------------------------------ ---------------------------------- ---------------------------------- ---------------------------------- -----
  **Hips:**                    Not done/Missing                    63                                 0                                  3[∞](#TFN8){ref-type="table-fn"}   66
                               Not Involved                        49                                 0                                  4[∞](#TFN8){ref-type="table-fn"}   53
                               ON; \< 30% Epiphyseal involvement   1[•](#TFN7){ref-type="table-fn"}   1                                  0                                  2
                               ON; ≥ 30% Epiphyseal involvement    1[•](#TFN7){ref-type="table-fn"}   0                                  2                                  3
                               Total                               114                                1                                  9                                  124
                                                                                                                                                                            
  **Knees:**                   Not done/Missing                    59                                 8[∞](#TFN8){ref-type="table-fn"}   5[∞](#TFN8){ref-type="table-fn"}   72
                               Not Involved                        34                                 7[∞](#TFN8){ref-type="table-fn"}   5[∞](#TFN8){ref-type="table-fn"}   46
                               ON; \< 30% Epiphyseal involvement   2[•](#TFN7){ref-type="table-fn"}   7                                  1                                  10
                               ON; ≥ 30% Epiphyseal involvement    0                                  1[±](#TFN9){ref-type="table-fn"}   0                                  1
                               Total                               95                                 23                                 11                                 129

Abbreviations: alloHCT, allogeneic hematopoietic stem cell transplantation; MR, magnetic resonance imaging; ON, osteonecrosis

Cases that showed complete resolution;

New lesions identified during first year

Cases that showed regression of the osteonecrosis lesion

###### 

Longitudinal changes in the osteonecrotic lesions in children observed with magnetic resonance imaging during the second year after alloHCT.

  One year post alloHCT MR imaging results   Two year post alloHCT MR imaging results   Total                                                                                                               
  ------------------------------------------ ------------------------------------------ ------- ----------------------------------- ----------------------------------- ----------------------------------- -----
  **Hips:**                                   Not done/Missing                          12      2                                   0                                   0                                   14
                                              Not Involved                              58      55                                  0                                   1[∞](#TFN11){ref-type="table-fn"}   114
                                              ON; \< 30% Epiphyseal involvement         0       0                                   1                                   0                                   1
                                              ON; ≥ 30% Epiphyseal involvement          3       0                                   1[±](#TFN12){ref-type="table-fn"}   5                                   9
                                              Total                                     73      57                                  2                                   6                                   138
                                                                                                                                                                                                            
  **Knees:**                                  Not done/Missing                          6       2                                   0                                   1[∞](#TFN11){ref-type="table-fn"}   9
                                              Not Involved                              53      38                                  4[∞](#TFN11){ref-type="table-fn"}   0                                   95
                                              ON; \< 30% Epiphyseal involvement         7       4[•](#TFN13){ref-type="table-fn"}   11                                  1                                   23
                                              ON; ≥ 30% Epiphyseal involvement          2       0                                   1[±](#TFN12){ref-type="table-fn"}   8                                   11
                                              Total                                     68      44                                  16                                  10                                  138

Abbreviations: MR, magnetic resonance imaging; ON, osteonecrosis

New cases identified with osteonecrosis during second year after allogeneic HCT

Case that showed regression in the size of the osteonecrosis lesions after allogeneic HCT

Cases that showed complete resolution

###### 

Risk factor analysis for osteonecrosis after alloHCT

  Univariate analysis using GEE model                                                                                                
  ----------------------------------------------------------------- ----------------------------------------- ---------------------- -----------------------------------------
  BMI at alloHCT                                                    Normal Underweight                        0.86(0.40 to 1.83)     0.6925
                                                                    Overweight Obese                                                 
  Gender                                                            Female                                    1.81(0.87 to 3.74)     0.1108
                                                                    Male                                                             
  Race                                                              Black                                     2.09(0.87 to 5.05)     0.1011
                                                                    Other                                     0.49(0.06 to 4.25)     0.5138
                                                                    White                                                            
  Diagnosis type                                                    Malignant                                 1.04(0.43 to 2.50)     0.9283
                                                                    Non-malignant                                                    
  Primary Diagnosis                                                 Lymphoid Malignancies + Aplastic Anemia   1.40(0.68 to 2.88)     0.3662
                                                                    Others                                                           
  Age at alloHCT                                                    Age at alloHCT \<10                       0.15(0.06 to 0.37)     \<.0001
                                                                    Age at alloHCT \>=10                                             
  Chronic GVHD grade                                                Extensive                                 1.33(0.55 to 3.21)     0.5302
                                                                    Limited                                   1.33 (0.48 to 3.64)    0.5819
                                                                    No chronic GVHD                                                  
  Acute GVHD Maximum Overall Grade                                  No acute GVHD grade ≥ 1                   0.82(0.32 to 2.12)     0.6834
  Physis Status                                                     Closed                                    3.33(1.55 to 7.15)     0.0020
                                                                    Open                                                             
  Donor Type                                                        Related                                   1.78(0.82 to 3.89)     0.1465
                                                                    Unrelated                                                        
  Conditioning regimen                                              NO TBI                                    1.16(0.54 to 2.51)     0.7020
                                                                    TBI                                                              
  Duration of Chronic GVHD, 6 months                                No prior chronic GVHD                                            
                                                                    Duration \<= 6 month                      1.29(0.56 to 2.95)     0.5455
                                                                    Duration \> 6 month                       1.42(0.44 to 4.58)     0.5546
  Pre-alloHCT MR                                                    Involved                                  14.19(3.52 to 57.27)   0.0002
                                                                    Not done/Missing                          0.75(0.33 to 1.74)     0.5074
                                                                    Not involved                                                     
                                                                                                                                     
  **Multiple GEE model analysis**[⫲](#TFN15){ref-type="table-fn"}                                                                    
  **Variable**                                                      **Clinical Level**                        **95% CI of OR**       **P Values**
  Pre-alloHCT MR                                                    Involved                                  13.50(2.64 to 68.92)   0.0018
                                                                    Not Involved                              0.86(0.30 to 2.51)     0.7867
                                                                    Not done/Missing                                                 
  Physis                                                            Closed                                    1.42(0.41 to 4.94)     0.5827
                                                                    Open                                                             
  Age at alloHCT                                                    Age at HCT \<10                           0.25(0.06 to 1.01)     
                                                                    Age at HCT \>=10                          4.00 (1.00 to 16.7)    0.0518
  Race                                                              Black                                     2.64(0.82 to 8.52)     0.1046[\#](#TFN16){ref-type="table-fn"}
                                                                    Other                                     0.53(0.05 to 5.44)     0.5925[\#](#TFN16){ref-type="table-fn"}
                                                                    White                                                            
  Gender                                                            Female                                    1.10(0.42 to 2.86)     0.8462
                                                                    Male                                                             

Abbreviations: alloHCT, allogeneic hematopoietic stem cell transplantation; BMI, body mass index; GVHD, graft vs. host disease; TBI, total body irradiation; MR, magnetic resonance imaging

Only factors significant (0.1 significant level) from univariate GEE model were included in this model

For race analysis sickle cell patients were excluded.
